viewStarton Therapeutics

Starton Therapeutics moves closer to treating CLL by selecting lead formulation candidate

Starton Therapeutics Inc CEO Pedro Lichtinger tells Proactive the privately-held, Paramus, New Jersey-based group has selected a subcutaneous (under the skin) lenalidomide formulation as the lead formulation candidate for its continuous subcutaneous delivery system (STAR-LLD SC) for chronic lymphocytic leukemia, which is a type of cancer of the blood and bone marrow, and other hematological malignancies.

Lichtinger says STAR-LLD SC clinical trial materials are expected to be shipped in the second quarter of 2021 for initiation of Phase 1/2 clinical studies for CLL in the second half of 2021. This moves the group closer to producing a product to benefit patients.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Starton Therapeutics named herein, including the promotion by the Company of Starton Therapeutics in any Content on the Site, the Company...


Proactive's One2One Investor Forum - Starton Therapeutics

Starton Therapeutics CEO Pedro Lichtinger presents to investors at Proactive's One2One Investor Forum. The privately-held New York based group uses transdermal technology with proprietary drivers to obtain new indications or develop on-label superiority for patients with hematological...

on 08/26/2020

2 min read